Kodiak Sciences (KOD) news

Kodiak Sciences (KOD) shares fell 7.78% intraday as investors took profits following a significant rally triggered by positive Phase 3 trial data for DAYBREAK in late September.

Kodiak Sciences (KOD) shares declined 7.78% intraday on October 13, 2026, as investors began to take profits following a notable rally in late September. The surge in share price was driven by the release of positive Phase 3 trial data for DAYBREAK, a key development for the company’s pipeline.…

Kodiak Sciences shares soar by a record 178%

Kodiak Sciences Inc. (KOD) has seen its shares surge by a record 178% year to date as of September 2026, outperforming the broader biotech sector, which has declined by 0.3% . The stock's strong performance follows the release of positive phase III trial data for its lead candidate, Zenkuda…

ImportantKodiak Sciences (KOD) shares surged 176.66% in intraday trading after the company announced positive top-line results from its Phase 3 DAYBREAK clinical trial for wet age-related macular degeneration.

Kodiak Sciences Inc.: H.C. Wainwright raises target price to $96 from $58

HC Wainwright reiterated its "Buy" rating on Kodiak Sciences (NASDAQ: KOD) and set a $58 price target for the stock, indicating upside of approximately 77% from its current price of $32.77. The firm's analysis highlights confidence in the company's development pipeline, particularly its lead…

Kodiak Sciences shares up 123% after co's eye-disease drugs meet trial goals